Characterization of Gut Microbiota in Chronic Liver Disease With Decreased Muscle Mass

NCT05729269 — Completed, 283 participants, Chuncheon Sacred Heart Hospital

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT05729269
StatusCompleted
Study typeObservational
Enrollment283 (Actual)
SponsorChuncheon Sacred Heart Hospital (Other); collaborators: Dongtan Sacred Heart Hospital, Hallym University Medical Center, Hangang Sacred Heart Hospital, Kangdong Sacred Heart Hospital, Yonsei University
ConditionsGastrointestinal Microbiome, Sarcopenia, Liver Disease Chronic
InterventionsSarcopenia_CT (Diagnostic test)
Datesstart 2017-03-22, primary completion 2019-04-30, completion 2021-12-31, first posted 2023-02-15, last updated 2023-02-15
Locations1 site in South Korea

Related Papers Related Patents Related Grants Related Experts
All trials for Gastrointestinal Microbiome All trials for Sarcopenia All trials of Sarcopenia_CT

-Summary

The purpose of this study was to confirm the presence of specific gut microbiota observed in patients with sarcopenia among patients who agreed to analyze gut microbiota through stool among multi-center chronic liver disease cohort patients.

Expand all sections  ·  Collapse all

+Detailed description

The effect of gut microbiota on liver disease is also well known and many studies are ongoing. A recently published study summarized the differences in the composition of gut microbiota in non-alcoholic fatty liver, steatohepatitis, and cirrhosis, and reported that metabolites from the changed gut microbiota may be a factor influencing non-alcoholic fatty liver disease (NAFLD) progression. These changes in gut microbiota composition have been reported to affect clinical outcomes in patients by causing an increase in endotoxin, a change in bile acid metabolism, and a decrease in short chain fatty acid. In particular, the reduction of short chain fatty acid is known to be associated with the occurrence of sarcopenia. Sarcopenia, which is common in patients with cirrhosis, which is a representative chronic liver disease, is well known as a poor prognostic factor for patients. Therefore, this study aims to analyze the distribution of gut microbiota observed in patients with sarcopenia through the gut microbiota investigated in the chronic liver disease cohort patient group and the characteristics of the distribution of gut microbiota for each disease corresponding to chronic liver disease.

+Arms and interventions

ArmTypeInterventionsDescription
Chronic liver diseaseDiagnostic Test: Sarcopenia_CTnon-alcohol liver disease, alcohol liver disease, liver cirrhosis
  • Sarcopenia_CT (Diagnostic test): measurement of skeletal muscle through abdominal computed tomography

+Outcome measures

Primary outcomes

  • Fecal gut microbiota between sarcopenia group and non-sarcopenia group [2 years]: Compare the species and proportions of the gut microbiota between sarcopenia group and non-sarcopenia group

+Eligibility

Sex: All, ages: 24 Years to 82 Years

Inclusion Criteria:

* 1\. Patients who have chronic liver disease (chronic liver disease cohort): alcohol liver disease, non-alcoholic liver disease, liver cirrhosis 2. Patients who consented to a study confirming the gut microbiota 3. Patients with abdominal computed tomography scan taken one month before or after submitting stool for gut microbiota analysis

Exclusion Criteria:

* Patients whose height and weight records are missing from the chart review

+Locations (1)

FacilityCityCountryStatus
Department of Internal Medicine, Hallym University Medical CollegeChuncheon, Gangwon-doSouth Korea